{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:17Z","timestamp":1791232457842,"version":"4.1.0"},"reference-count":77,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To create a model in which to study the effects of RAS dysregulation in hematopoietic disease, we developed separate founder lines of transgenic mice, with the tetracycline transactivator (tTA) driven by the Vav hematopoietic promoter in one line and NRASV12 driven by the tetracycline responsive element (TRE2) in the other. When these lines are crossed, doubly transgenic animals uniformly develop a disease similar to human aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) when they are between 2 and 4 months of age. Disease is characterized by tissue infiltrates of large, well-differentiated mast cells in the spleen, liver, skin, lung, and thymus. Analysis of bone sections shows small to large foci of similarly well-differentiated mast cells. Results also show that transgene expression and diseases are repressible through the administration of doxycycline in the drinking water of affected animals, indicating that NRASV12 expression is required to initiate and maintain disease in doubly transgenic mice. Our inducible system of transgenes, developed as a model of mutant NRASV12 oncogene\u2013driven myeloid disease, will be useful for studying the role of RAS dysregulation in hematopoietic disease in general and in discrete human diseases, specifically ASM and MCL.<\/jats:p>","DOI":"10.1182\/blood-2004-08-3306","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T20:24:59Z","timestamp":1113510299000},"page":"1054-1062","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Repressible transgenic model of NRAS oncogene\u2013driven mast cell disease in the mouse"],"prefix":"10.1182","volume":"106","author":[{"given":"Stephen M.","family":"Wiesner","sequence":"first","affiliation":[{"name":"From the University of Minnesota Comprehensive Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M.","family":"Jones","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Comprehensive Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Hasz","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Comprehensive Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Largaespada","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Comprehensive Cancer Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223171128400_REF1","doi-asserted-by":"crossref","unstructured":"Casey G, Rudzki Z, Roberts M, Hutchins C, Juttner C. N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology. 1993;25: 57-62.","DOI":"10.3109\/00313029309068903"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995;86: 4579-4586.","DOI":"10.1182\/blood.V86.12.4579.bloodjournal86124579"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Lee YY, Kim WS, Bang YJ, et al. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. Stem Cells. 1995;13: 556-563.","DOI":"10.1002\/stem.5530130514"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Neubauer A, Shannon K, Liu E. Mutation of the ras proto-oncogenes in childhood monosomy 7. Blood. 1991;77: 594-598.","DOI":"10.1182\/blood.V77.3.594.594"},{"key":"2020021223171128400_REF5","doi-asserted-by":"crossref","unstructured":"Radich JP, Kopecky KJ, Willman CL, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990;76: 801-807.","DOI":"10.1182\/blood.V76.4.801.801"},{"key":"2020021223171128400_REF6","unstructured":"Gaidano G, Guerrasio A, Serra A, Rege-Cambrin G, Saglio G. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia. 1994;(suppl 1): S27-S29."},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109: 335-346.","DOI":"10.1016\/S0092-8674(02)00734-1"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Serra A, Guerrasio A, Gaidano G, et al. Molecular defects associated with the acute phase CML. Leuk Lymphoma. 1993;(suppl 1): 25-28.","DOI":"10.3109\/10428199309047858"},{"key":"2020021223171128400_REF9","doi-asserted-by":"crossref","unstructured":"Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18: 466-475.","DOI":"10.1038\/sj.leu.2403274"},{"key":"2020021223171128400_REF10","doi-asserted-by":"crossref","unstructured":"Ayllon V, Rebollo A. Ras-induced cellular events (review). Mol Membr Biol. 2000;17: 65-73.","DOI":"10.1080\/09687680050117093"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3: 179-198.","DOI":"10.1146\/annurev.genom.3.032802.115046"},{"key":"2020021223171128400_REF12","doi-asserted-by":"crossref","unstructured":"Scheele JS, Ripple D, Lubbert M. The role of ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation. Cell Mol Life Sci. 2000;57: 1950-1963.","DOI":"10.1007\/PL00000675"},{"key":"2020021223171128400_REF13","doi-asserted-by":"crossref","unstructured":"Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108: 322-330.","DOI":"10.1046\/j.1365-2141.2000.01831.x"},{"key":"2020021223171128400_REF14","doi-asserted-by":"crossref","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532-1542.","DOI":"10.1182\/blood-2002-02-0492"},{"key":"2020021223171128400_REF15","doi-asserted-by":"crossref","unstructured":"Futatsugi N, Tsuda M. Molecular dynamics simulations of Gly-12\u2192Val mutant of p21(ras): dynamic inhibition mechanism. Biophys J. 2001;81: 3483-3488.","DOI":"10.1016\/S0006-3495(01)75979-6"},{"key":"2020021223171128400_","unstructured":"Howe LR, Marshall CJ. Identification of amino acids in p21ras involved in exchange factor interaction. Oncogene. 1993;8: 2583-2590."},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Quilliam LA, Hisaka MM, Zhong S, et al. Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. J Biol Chem. 1996;271: 11076-11082.","DOI":"10.1074\/jbc.271.19.11076"},{"key":"2020021223171128400_REF18","doi-asserted-by":"crossref","unstructured":"Stone JC, Colleton M, Bottorff D. Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction. Mol Cell Biol. 1993;13: 7311-7320.","DOI":"10.1128\/MCB.13.12.7311"},{"key":"2020021223171128400_REF19","doi-asserted-by":"crossref","unstructured":"Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte\/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12: 137-143.","DOI":"10.1038\/ng0296-137"},{"key":"2020021223171128400_REF20","unstructured":"Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol. 1999;36: 59-72."},{"key":"2020021223171128400_REF21","doi-asserted-by":"crossref","unstructured":"Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91: 419-430.","DOI":"10.1182\/blood.V91.2.419"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94: 1855-1863.","DOI":"10.1182\/blood.V94.6.1855"},{"key":"2020021223171128400_REF23","doi-asserted-by":"crossref","unstructured":"Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999;96: 14943-14948.","DOI":"10.1073\/pnas.96.26.14943"},{"key":"2020021223171128400_REF24","doi-asserted-by":"crossref","unstructured":"Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating notch signaling with thymocyte maturation. Immunity. 1998;9: 777-786.","DOI":"10.1016\/S1074-7613(00)80643-3"},{"key":"2020021223171128400_REF25","doi-asserted-by":"crossref","unstructured":"Attal J, Theron MC, Houdebine LM. The optimal use of IRES (internal ribosome entry site) in expression vectors. Genet Anal. 1999;15: 161-165.","DOI":"10.1016\/S1050-3862(99)00021-2"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Hennecke M, Kwissa M, Metzger K, et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res. 2001;29: 3327-3334.","DOI":"10.1093\/nar\/29.16.3327"},{"key":"2020021223171128400_REF27","doi-asserted-by":"crossref","unstructured":"Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17: 157-165.","DOI":"10.1016\/S1389-0344(01)00067-3"},{"key":"2020021223171128400_REF28","doi-asserted-by":"crossref","unstructured":"Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100: 238-245.","DOI":"10.1182\/blood.V100.1.238"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91: 612-624.","DOI":"10.1016\/0002-9343(91)90214-I"},{"key":"2020021223171128400_REF30","doi-asserted-by":"crossref","unstructured":"Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25: 603-625.","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"2020021223171128400_REF31","unstructured":"Kiernan JA. Production and life span of cutaneous mast cells in young rats. J Anat. 1979;128: 225-238."},{"key":"2020021223171128400_REF32","doi-asserted-by":"crossref","unstructured":"Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic K-ras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101: 597-602.","DOI":"10.1073\/pnas.0307203101"},{"key":"2020021223171128400_REF33","doi-asserted-by":"crossref","unstructured":"Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113: 528-538.","DOI":"10.1172\/JCI20476"},{"key":"2020021223171128400_REF34","unstructured":"Dunbar CE, Crosier PS, Nienhuis AW. Introduction of an activated RAS oncogene into murine bone marrow lymphoid progenitors via retroviral gene transfer results in thymic lymphomas. Oncogene Res. 1991;6: 39-51."},{"key":"2020021223171128400_REF35","unstructured":"Hawley RG, Fong AZ, Ngan BY, Hawley TS. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene. 1995;11: 1113-1123."},{"key":"2020021223171128400_REF36","doi-asserted-by":"crossref","unstructured":"Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumor predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7: 353-361.","DOI":"10.1038\/ng0794-353"},{"key":"2020021223171128400_REF37","doi-asserted-by":"crossref","unstructured":"Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187: 1893-1902.","DOI":"10.1084\/jem.187.11.1893"},{"key":"2020021223171128400_REF38","doi-asserted-by":"crossref","unstructured":"Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90: 479-488.","DOI":"10.1182\/blood.V90.2.479"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today. 1996;2: 468-475.","DOI":"10.1016\/1357-4310(96)10044-7"},{"key":"2020021223171128400_REF40","unstructured":"Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases: European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89: 3534-3543."},{"key":"2020021223171128400_REF41","doi-asserted-by":"crossref","unstructured":"Elefanty AG, Cory S. Hematologic disease induced in BALB\/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Mol Cell Biol. 1992;12: 1755-1763.","DOI":"10.1128\/MCB.12.4.1755"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Elefanty AG, Cory S. bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro. Blood. 1992;79: 1271-1281.","DOI":"10.1182\/blood.V79.5.1271.1271"},{"key":"2020021223171128400_REF43","doi-asserted-by":"crossref","unstructured":"Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9: 1069-1078.","DOI":"10.1002\/j.1460-2075.1990.tb08212.x"},{"key":"2020021223171128400_REF44","doi-asserted-by":"crossref","unstructured":"MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 1999;93: 2043-2056.","DOI":"10.1182\/blood.V93.6.2043.406k17_2043_2056"},{"key":"2020021223171128400_REF45","doi-asserted-by":"crossref","unstructured":"Guo X, Schrader KA, Xu Y, Schrader JW. Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis\/mast cell leukemia, distinct from the histiocytosis\/monocytic leukemia induced by expression of activated H-Ras. Oncogene. 2005;24: 2330-2342.","DOI":"10.1038\/sj.onc.1208441"},{"key":"2020021223171128400_REF46","doi-asserted-by":"crossref","unstructured":"Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002;13: 1438-1446.","DOI":"10.1093\/annonc\/mdf226"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Bivona TG, Perez De Castro I, Ahearn IM, et al. Phospholipase C\u03b3 activates Ras on the Golgi apparatus by means of RasGRP1. Nature. 2003;424: 694-698.","DOI":"10.1038\/nature01806"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Caloca MJ, Zugaza JL, Bustelo XR. Exchange factors of the RasGRP family mediate Ras activation in the Golgi. J Biol Chem. 2003;278: 33465-33473.","DOI":"10.1074\/jbc.M302807200"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Chiu VK, Bivona T, Hach A, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002;4: 343-350.","DOI":"10.1038\/ncb783"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Choy E, Chiu VK, Silletti J, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell. 1999;98: 69-80.","DOI":"10.1016\/S0092-8674(00)80607-8"},{"key":"2020021223171128400_","unstructured":"Conzelmann M, Linnemann U, Berger MR. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int J Oncol. 2004;24: 1537-1544."},{"key":"2020021223171128400_REF52","doi-asserted-by":"crossref","unstructured":"Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell. 1990;63: 133-139.","DOI":"10.1016\/0092-8674(90)90294-O"},{"key":"2020021223171128400_REF53","doi-asserted-by":"crossref","unstructured":"Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15: 3249-3262.","DOI":"10.1101\/gad.947701"},{"key":"2020021223171128400_REF54","doi-asserted-by":"crossref","unstructured":"Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410: 1111-1116.","DOI":"10.1038\/35074129"},{"key":"2020021223171128400_REF55","doi-asserted-by":"crossref","unstructured":"Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 2003;3: 375-380.","DOI":"10.1038\/nrc1070"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol. 2004;14: 3-11.","DOI":"10.1016\/j.semcancer.2003.11.002"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6: 577-586.","DOI":"10.1016\/j.ccr.2004.10.013"},{"key":"2020021223171128400_REF58","doi-asserted-by":"crossref","unstructured":"D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous K-ras2 mutations. Nat Med. 2001;7: 235-239.","DOI":"10.1038\/84691"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4: 199-207.","DOI":"10.1016\/S1097-2765(00)80367-6"},{"key":"2020021223171128400_","unstructured":"Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004;6: 535-538."},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis [abstract]. BMC Biol. 2004;2: 26.","DOI":"10.1186\/1741-7007-2-26"},{"key":"2020021223171128400_REF62","doi-asserted-by":"crossref","unstructured":"Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431: 1112-1117.","DOI":"10.1038\/nature03043"},{"key":"2020021223171128400_REF63","doi-asserted-by":"crossref","unstructured":"Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297: 102-104.","DOI":"10.1126\/science.1071489"},{"key":"2020021223171128400_REF64","doi-asserted-by":"crossref","unstructured":"Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer. 2004;110: 336-342.","DOI":"10.1002\/ijc.20099"},{"key":"2020021223171128400_REF65","doi-asserted-by":"crossref","unstructured":"Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400: 468-472.","DOI":"10.1038\/22788"},{"key":"2020021223171128400_REF66","doi-asserted-by":"crossref","unstructured":"Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24: 57-60.","DOI":"10.1038\/71691"},{"key":"2020021223171128400_REF67","doi-asserted-by":"crossref","unstructured":"Nowicki MO, Falinski R, Koptyra M, et al. BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104: 3746-3753.","DOI":"10.1182\/blood-2004-05-1941"},{"key":"2020021223171128400_REF68","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92: 10560-10564.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2020021223171128400_REF69","doi-asserted-by":"crossref","unstructured":"Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97: 3559-3567.","DOI":"10.1182\/blood.V97.11.3559"},{"key":"2020021223171128400_REF70","doi-asserted-by":"crossref","unstructured":"Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31: 1053-1074.","DOI":"10.1016\/S1357-2725(99)00078-3"},{"key":"2020021223171128400_REF71","doi-asserted-by":"crossref","unstructured":"Sundstrom M, Vliagoftis H, Karlberg P, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003;108: 89-97.","DOI":"10.1046\/j.1365-2567.2003.01559.x"},{"key":"2020021223171128400_REF72","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Semere T, Metcalfe DD. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis. Leukemia. 1998;12: 175-181.","DOI":"10.1038\/sj.leu.2400906"},{"key":"2020021223171128400_REF73","doi-asserted-by":"crossref","unstructured":"Escribano L, Diaz Agustin B, Bravo P, Navalon R, Almeida J, Orfao A. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma. 1999;35: 227-235.","DOI":"10.3109\/10428199909145725"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25: 563-570.","DOI":"10.1016\/S0145-2126(01)00050-9"},{"key":"2020021223171128400_","doi-asserted-by":"crossref","unstructured":"Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91: 2731-2736.","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736"},{"key":"2020021223171128400_REF76","doi-asserted-by":"crossref","unstructured":"Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117\/Kit, and bcl-x(L). Hum Pathol. 2001;32: 545-552.","DOI":"10.1053\/hupa.2001.24319"},{"key":"2020021223171128400_REF77","unstructured":"Janeway CA, Travers P, Walport M, Capra JD, eds. Immunobiology: The Immune System in Health and Disease. 4th ed. New York, NY: Elsevier Science Ltd\/Garland Publishing; 1999."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/1054\/1711909\/zh801505001054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/1054\/1711909\/zh801505001054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T18:08:15Z","timestamp":1586196495000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/3\/1054\/21879\/Repressible-transgenic-model-of-NRAS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-08-3306","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}